Portosystemic Shunt-associated Pulmonary Hypertension Multi-center Prospective Cohort Study
NCT07481877 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2026-03-19
Summary
This study aims to establish a multi-center registry cohort of portosystemic shunt-associated pulmonary hypertension, with the goal of clarifying the epidemiology, clinical features, phenotypic classification, response to targeted therapy, and prognostic outcomes in patients with portosystemic shunt-associated pulmonary hypertension.
Conditions
- Portosystemic Shunt
- Pulmonary Hypertension
Sponsors & Collaborators
-
Chinese Pulmonary Vascular Disease Research Group
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-01
- Primary Completion
- 2031-04-01
- Completion
- 2031-04-01
More Related Trials
-
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study
NCT05372263 ·Status: RECRUITING
-
Pulmonary Hypertension--Mechanisms and Family Registry
NCT00005357 ·Status: COMPLETED
-
Utility of Exercise-induced N-terminal (NT) Pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis
NCT00567437 ·Status: TERMINATED ·Phase: NA
-
Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension
NCT05437224 ·Status: COMPLETED ·Phase: PHASE3
-
The Effects of Pulmonary Hypertension Web-Based Health Care Program on Symptom Management, Social Support, Activity Tolerance, and Quality of Life in Patients With Pulmonary Hypertension.
NCT05908019 ·Status: UNKNOWN ·Phase: NA
-
Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan
NCT01508780 ·Status: WITHDRAWN ·Phase: PHASE4
-
Efficacy of Triple-Combination Therapy in Severe PAH-CHD
NCT06196801 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension
NCT07177703 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Real-World Registry Investigating TReprostInil sodiUM in Pulmonary Hypertension (Re-TRIUMPH)
NCT05553015 ·Status: RECRUITING
-
rhBNP in Type 3 Pulmonary Hypertension
NCT05716984 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Evaluation of Lung Doppler Signals in Pulmonary Hypertension
NCT01839786 ·Status: TERMINATED
-
Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension
NCT00675051 ·Status: COMPLETED
-
Assessing the Utility of Submaximal CPET in Treatment Management of PAH
NCT05977933 ·Status: NOT_YET_RECRUITING
-
Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH
NCT07357974 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
FreeFlow Percutaneous Atrial Septal Shunt for IPAH
NCT06605794 ·Status: RECRUITING ·Phase: NA
-
Zürich Pulmonary Hypertension Outcome Assessment Cohort
NCT02249806 ·Status: UNKNOWN
-
Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension
NCT06987097 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Endothelial Cell Activation and Total Pulmonary Resistance in PAH
NCT06035861 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Point of Care Ultrasonography Assessment During Pulmonary Hypertension Clinic
NCT05332847 ·Status: COMPLETED ·Phase: NA
-
Empagliflozin in Pulmonary Arterial Hypertension
NCT05493371 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
NCT05818137 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants
NCT04955990 ·Status: TERMINATED ·Phase: PHASE4
-
Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study
NCT06605326 ·Status: COMPLETED ·Phase: PHASE4
-
Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension
NCT07453030 ·Status: NOT_YET_RECRUITING
-
Pharmacogenomics in Pulmonary Arterial Hypertension
NCT00593905 ·Status: WITHDRAWN